Back

Transition of patients with familial chylomicronaemia syndrome from volanesorsen to olezarsen: safety and pharmacokinetic results

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Secondary prevention: a multifactorial approach Drug therapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Daniel Gaudet

ECOGENE-21 and Community gene medicine center, clinical lipidology unit, Montreal (Canada)

9 More presentations in this session

Presentation thumbnail
Comprehensive risk factor management through a dedicated secondary prevention clinic: experience from hamilton, Ontario
Miss C. Frketich (Hamilton, CA)
Abstract Slides Video
Presentation thumbnail
Variability of pre-test probability for obstructive coronary artery disease between referring primary care physicians and estimations from the referral letters
Mr E. Stertman (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Integrated care using the ABC-stroke pathway improves cardiovascular outcomes and survival in patients with recent ischaemic stroke: a population-based cohort study
Doctor S. Choi (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Long-term continuation to pharmacological treatment for secondary prevention after a myocardial infarction: a register study
Ms M. Sakalaki (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
National dispensing of evidence-based treatment for New Zealand patients before and after peripheral arterial or percutaneous coronary procedures; undertreatment in plain sight.
Associate Professor S. Wells (Auckland, NZ)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention: a multifactorial approach

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources